Completion Date

Spring 4-18-2023

Document Type


Degree Name

Master of Science (MS)

Program or Discipline Name


First Advisor

Leena Pattarkine


mRNA vaccines have been established as a promising alternative to conventional vaccines over the last decade. mRNA therapeutics do not use inactivated viruses, which makes them non-immunogenic, easily degradable and without possessing the risk of insertional mutagenesis. mRNA vaccines use a standard platform for development of prophylactic and infectious diseases which makes mRNA vaccine platform a breakthrough technology in the field of therapeutics. Various aspects of mRNA structure come into play when developing mRNA vaccines and this review focuses on the translation, stability, immunogenicity related to mRNA vaccines and their delivery methods. The nuances of testing the quality of mRNA vaccines, regulatory aspects and market trends are covered in the review would provide a more comprehensive review of mRNA vaccines in addition to the scientific and technical aspects.